169 related articles for article (PubMed ID: 35664314)
1. NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers.
Wang Z; Yang H; Luo B; Duan P; Lin P
Front Genet; 2022; 13():805256. PubMed ID: 35664314
[No Abstract] [Full Text] [Related]
2. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
3. Four Immune-Related Genes (FN1, UGCG, CHPF2 and THBS2) as Potential Diagnostic and Prognostic Biomarkers for Carbon Nanotube-Induced Mesothelioma.
Xie D; Hu J; Wu T; Cao K; Luo X
Int J Gen Med; 2021; 14():4987-5003. PubMed ID: 34511983
[TBL] [Abstract][Full Text] [Related]
4. CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma.
Liu L; Hui R; Zeng T; Yang X; Wu Q; Yang T
Int J Gen Med; 2022; 15():4613-4623. PubMed ID: 35535145
[TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma.
Xu X; Cheng L; Fan Y; Mao W
Front Oncol; 2020; 10():544789. PubMed ID: 33042835
[TBL] [Abstract][Full Text] [Related]
6. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
7. Identification of Potential Hub Genes and Therapeutic Drugs in Malignant Pleural Mesothelioma by Integrated Bioinformatics Analysis.
Zhang X; Yang L; Chen W; Kong M
Oncol Res Treat; 2020; 43(12):656-671. PubMed ID: 33032291
[TBL] [Abstract][Full Text] [Related]
8. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
9. Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma.
Yeo D; Castelletti L; van Zandwijk N; Rasko JEJ
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439085
[TBL] [Abstract][Full Text] [Related]
10. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
[TBL] [Abstract][Full Text] [Related]
11. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification.
Alay A; Cordero D; Hijazo-Pechero S; Aliagas E; Lopez-Doriga A; Marín R; Palmero R; Llatjós R; Escobar I; Ramos R; Padrones S; Moreno V; Nadal E; Solé X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632900
[TBL] [Abstract][Full Text] [Related]
12. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
13. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
14. In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
Rouka E; Beltsios E; Goundaroulis D; Vavougios GD; Solenov EI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212858
[No Abstract] [Full Text] [Related]
15. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
16. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
18. Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer.
Liu M; Wei H; Yang J; Chen X; Wang H; Zheng Y; Wang Y; Zhou Y
Front Genet; 2022; 13():916973. PubMed ID: 35846126
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
[TBL] [Abstract][Full Text] [Related]
20. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
